PIGMENTED VILLONODULAR SYNOVITIS
Clinical trials for PIGMENTED VILLONODULAR SYNOVITIS explained in plain language.
Never miss a new study
Get alerted when new PIGMENTED VILLONODULAR SYNOVITIS trials appear
Sign up with your email to follow new studies for PIGMENTED VILLONODULAR SYNOVITIS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New pill targets rare joint tumors in major clinical trial
Disease control OngoingThis Phase 3 trial is testing whether an oral medication called ABSK021 (pimicotinib) can shrink tumors and improve symptoms in adults with tenosynovial giant cell tumor (TGCT), a rare, non-cancerous joint condition. The study will enroll 90 participants who cannot have their tum…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE3 • Sponsor: Abbisko Therapeutics Co, Ltd • Aim: Disease control
Last updated Apr 03, 2026 14:43 UTC
-
New drug trial targets rare joint tumor and advanced cancers
Disease control OngoingThis study is testing an experimental drug called vimseltinib in adults with advanced solid tumors or a rare joint tumor called tenosynovial giant cell tumor (TGCT). The first phase aims to find the safest and most effective dose. The second phase will focus on TGCT patients to s…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE1, PHASE2 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Mar 25, 2026 14:07 UTC
-
New drug trial offers hope for inoperable joint tumors
Disease control OngoingThis study is testing whether an experimental drug called vimseltinib can shrink tumors in people with tenosynovial giant cell tumor (TGCT) when surgical removal isn't an option. About 123 adults with symptomatic TGCT will receive either vimseltinib or a placebo for 24 weeks, wit…
Matched conditions: PIGMENTED VILLONODULAR SYNOVITIS
Phase: PHASE3 • Sponsor: Deciphera Pharmaceuticals, LLC • Aim: Disease control
Last updated Mar 24, 2026 12:02 UTC